Home
HelpTest ID: PARDP Inherited Parkinson Disease Gene Panel, Varies
Ordering Guidance
Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.
The following documents are available
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
2. Molecular Genetics: Neurology Patient Information
3. If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Useful For
Establishing a molecular diagnosis for patients with Parkinson disease
Identifying variants within genes known to be associated with Parkinson disease, allowing for predictive testing of at-risk family members
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 94 genes associated with Parkinson disease: ADORA1, AHSA1, ANG, ANO3, APP, ATP13A2, ATP1A3, ATP6AP2, ATP7B, C19orf12, CHCHD2, CHMP2B, CLN3, CP, CSF1R, CYP27A1, DCAF17, DCTN1, DDC, DNAJB2, DNAJC12, DNAJC13, DNAJC6, DNM1L, EIF4G1, FBXO7, FTL, FUS, GBA, GCH1, GIGYF2, GRN, HTRA2, KIF5A, LRP10, LRRK2, LYST, MAPT, OPTN, PANK2, PARK7, PDE10A, PDE8B, PDGFB, PDGFRB, PEX1, PINK1, PLA2G6, PLD3, PODXL, POLG, POLG2, PRKAR1B, PRKN, PRKRA, PRRT2, PSEN1, PSEN2, PTRHD1, RAB29, RAB39B, RIC3, SIGMAR1, SLC18A2, SLC20A2, SLC30A10, SLC39A14, SLC6A3, SNCA, SNCB, SOD1, SPG11, SPR, SQSTM1, SYNJ1, TAF1, TAF15, TARDBP, TENM4, TH, THAP1, TMEM230, TOR1A, TUBA4A, TWNK, UBQLN2, UCHL1, UNC13A, VCP, VPS13A, VPS13C, VPS35, WDR45, XPR1. For more information see Method Description and Targeted Genes and Methodology Details for Inherited Parkinson Disease Gene Panel.
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for Parkinson disease.
Method Name
Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
Parkinson Disease Gene PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | ||
Clinical Information
Parkinson disease is the second most common neurodegenerative movement disorder, and is characterized by rest tremor, muscle rigidity, bradykinesia, and postural instability. The most common nonmotor features include olfactory dysfunction, cognitive impairment, psychiatric symptoms, and autonomic dysfunction. Onset of disease is commonly around 60 years, but the juvenile form can have onset prior to age 20 years. Early-Parkinson disease has an onset between 20 to 50 years, and late-onset Parkinson disease occurs after age 50 years. The clinical diagnosis is based on parkinsonian motor features, namely bradykinesia plus rigidity and resting tremor. Parkinson disease results from interplay between nongenetic and genetic factors. Risk factors for Parkinson disease include sex, ethnicity, age, and environmental exposures. However, genetic factors are increasingly recognized as causative, with both known monogenic causes and susceptibility genes known.
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Clinical Reference
1. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-424.
2. Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018;42:72-85
3. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912
Day(s) Performed
Varies
Report Available
21 to 35 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81403
81404 x 3
81405 x 4
81406 x 9
81407
81408
81479
81479 (if appropriate for government payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PARDP | Parkinson Disease Gene Panel | 103956-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 617676 | Test Description | 62364-5 |
| 617677 | Specimen | 31208-2 |
| 617678 | Source | 31208-2 |
| 617679 | Result Summary | 50397-9 |
| 617680 | Result | 82939-0 |
| 617681 | Interpretation | 69047-9 |
| 618188 | Additional Results | 82939-0 |
| 617682 | Resources | 99622-3 |
| 617683 | Additional Information | 48767-8 |
| 617684 | Method | 85069-3 |
| 617685 | Genes Analyzed | 48018-6 |
| 617686 | Disclaimer | 62364-5 |
| 617687 | Released By | 18771-6 |
mcl-moltechtestmenu; mcl-neurology